Project Grant R01HL177566
Award Date
8/1/25
Completion Date
5/31/29
Dollars Obligated
$744K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Arizona, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program CFDA 93.837 - Cardiovascular Diseases Research, will support research to define cellular pathways that regulate lipid flux and elucidate their impact on cardiovascular disease. The $773,259 award, with a project period from December 2024 to November 2028, will enable the University of California, Los Angeles (UCLA) to: 1) Identify novel cholesterol-responsive proteins in the...
The University of Arizona was awarded a $625,316 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the role of RNA methylation and translational regulation in the oxidative stress response of heart failure. The research aims to elucidate how the YTHDF2 protein binds to methylated NRF2 mRNA to selectively induce its translation under oxidative stress, a process that may be impaired in end-stage heart failure. The...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $121,773 to the University of Arizona to investigate the role of the serum/glucocorticoid regulated kinase 1 (SGK1) in driving pathological cardiac hypertrophy. The research aims to determine if SGK1 is required for the development of cardiac hypertrophy and if impairing its degradation through the endoplasmic reticulum-associated degradation (ERAD)...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $618,045 to the University of Arizona to conduct research on identifying new mechanisms and targets for treating diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The primary objectives are to: 1) fully characterize at the atomic level three specific functional domains of the cardiac thin filament linked to the...
This $1,102,500 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research at the University of California, Los Angeles (UCLA) to address persistent problems in the field of intravascular triglyceride metabolism. The key focus areas include: Identifying sequences in apolipoprotein A5 (apoA5) that are important for suppressing the activity of the ANGPTL3/8 complex, and using that knowledge...
This $695,403.00 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop therapeutic approaches to improve lung microvascular integrity and inhibit the progression of pulmonary fibrosis. The key proposed activities include: Evaluating whether restoring microvascular integrity through nanoparticle gene therapy can inhibit lung fibrogenesis. Determining if transplantation of FOXF1+CKIT+ endothelial progenitor cells can...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of a lesion-targeted nanotherapeutic to address vascular smooth muscle cell (VSMC) dysfunction and mitigate neointimal hyperplasia (NIH), which is a significant issue arising from vascular damage during interventions. The project aims to integrate in vitro transcribed CARMN RNA (a long non-coding RNA critical...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, effective January 2, 2025 through December 31, 2027, will support the development of microphysiological systems to investigate molecular pathways and cardiomyocyte function in response to hypoxic cardiac injury associated with myocardial infarction and ischemia-reperfusion injury. The project aims to...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will provide $633,720 to The Washington University to conduct research on protein arginylation and its impact on cardiovascular health and development. The key objectives are to: Develop a chemical proteomics platform to comprehensively identify proteins that undergo arginylation in cardiac cells and tissues. This will involve mapping the "arginylome" and...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) totaling $706,220.00 supports research to elucidate the role of the nuclear pore protein NUP93 in regulating endothelial cell function and vascular health. The research aims to investigate how phosphorylation of NUP93 by the AKT signaling pathway impacts YAP localization and endothelial inflammation, as well as the in vivo importance of NUP93 phosphorylation in...